Please wait while the formulary information is being retrieved.
NICODERM CQ (nicotine)
- stop smoking
14 mg/24 hr daily transdermal patch
- Apply 1 patch (14 mg) by transdermal route once daily
21 mg/24 hr daily transdermal patch
- Apply 1 patch (21 mg) by transdermal route once daily and remove at bedtime
7 mg/24 hr daily transdermal patch
- Apply 1 patch (7 mg) by transdermal route once daily
nicotine 14 mg/24 hr daily transdermal patch
- Apply 1 patch (14 mg) by transdermal route once daily
nicotine 21 mg/24 hr daily transdermal patch
- Apply 1 patch (21 mg) by transdermal route once daily and remove at bedtime
nicotine 7 mg/24 hr daily transdermal patch
- Apply 1 patch (7 mg) by transdermal route once daily
14 mg/24 hr daily transdermal patch
- Apply 1 patch (14 mg) by transdermal route once daily
21 mg/24 hr daily transdermal patch
- Apply 1 patch (21 mg) by transdermal route once daily and remove at bedtime
7 mg/24 hr daily transdermal patch
- Apply 1 patch (7 mg) by transdermal route once daily
Default screening record
- Apply 1 patch (7 mg) by transdermal route once daily for 2 weeks
- Apply 1 patch (7 mg) by transdermal route once daily and remove at bedtime
- Apply 1 patch (7 mg) by transdermal route once daily for 2 weeks and remove at bedtime
- Apply 1 patch (7 mg) by transdermal route once daily for 4 weeks and remove at bedtime
- Apply 1 patch (7 mg) by transdermal route once daily
- Apply 1 patch (14 mg) by transdermal route once daily
- Apply 1 patch (14 mg) by transdermal route once daily for 4 weeks
- Apply 1 patch (14 mg) by transdermal route once daily for 8 weeks
- Apply 1 patch (14 mg) by transdermal route once daily and remove at bedtime
- Apply 1 patch (14 mg) by transdermal route once daily for 2 weeks andremove at bedtime
- Apply 1 patch (14 mg) by transdermal route once daily for 4 weeks andremove at bedtime
- Apply 1 patch (14 mg) by transdermal route once daily and remove at bedtime for 8 weeks
- Apply 1 patch (14 mg) by transdermal route once daily for 2 weeks
- Apply 1 patch (21 mg) by transdermal route once daily
- Apply 1 patch (21 mg) by transdermal route once daily for 4 weeks
- Apply 1 patch (21 mg) by transdermal route once daily for 6 weeks
- Apply 1 patch (21 mg) by transdermal route once daily for 4-6 weeks
- Apply 1 patch (21 mg) by transdermal route once daily for 8 weeks
- Apply 1 patch (21 mg) by transdermal route once daily and remove at bedtime
- Apply 1 patch (21 mg) by transdermal route once daily and remove at bedtime for 4 weeks
- Apply 1 patch (21 mg) by transdermal route once daily and remove at bedtime for 8 weeks
- Apply 1 patch (21 mg) by transdermal route once daily and remove at bedtime for 6 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Magnetic resonance imaging
Contraindicated
- 30 day risk period post-myocardial infarction
- Acute myocardial infarction
- Angina
- Buerger's disease
- Coronary artery disease
- Life-threatening cardiac arrhythmias
- Raynaud's phenomenon
- Severe uncontrolled hypertension
- Unstable angina pectoris
Severe
Moderate
- Contact dermatitis
- Diabetes mellitus
- Disease of liver
- Esophagitis
- Gastrointestinal ulcer
- Hyperthyroidism
- Kidney disease with likely reduction in GFR
- Lower seizure threshold
- Pheochromocytoma
- Prinzmetal angina
- Seizure disorder
NICODERM CQ (nicotine)
- stop smoking
- None
- Application site skin reactions
- Increased appetite
- Palpitations
- Tachycardia
More Frequent
Severe
Less Severe
- Dyspnea
- Abdominal pain with cramps
- Constipation
- Dizziness
- Dream disorder
- Drowsy
- Hyperhidrosis
- Nervousness
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Angioedema
- Atrial fibrillation
- Dermatitis due to topical drug
- Erythema
- Impaired wound healing
- Peptic ulcer
- Pruritus of skin
- Seizure disorder
- Skin burn caused by transdermal patch worn during MRI
- Urticaria
Less Severe
- Anorexia
- Arthralgia
- Concentration difficulty
- Cough
- Depression
- Diarrhea
- Dysmenorrhea
- Headache disorder
- Insomnia
- Irritability
- Localized edema
- Myalgia
- Nightmares
- Paresthesia
- Skin rash
- Vertigo
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Nicotine
Use may be considered for adolescents with clinician oversight. Safety and effectiveness not established age <18 years.
- 1 Day – 18 Years
- Use may be considered for adolescents with clinician oversight. Safety and effectiveness not established age <18 years.
Nicotine
- Severity Level:
2
- Additional Notes: Insufficient human data; consider risk of continued cig smoking vs benefit of tx
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Nicotine
Potential for serious adv eff, however benefit of maternal smoking cessation.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Potential for serious adv eff, however benefit of maternal smoking cessation. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Smoking cessation | |
| F17 | Nicotine dependence |
| F17.2 | Nicotine dependence |
| F17.20 | Nicotine dependence, unspecified |
| F17.200 | Nicotine dependence, unspecified, uncomplicated |
| F17.201 | Nicotine dependence, unspecified, in remission |
| F17.203 | Nicotine dependence unspecified, with withdrawal |
| F17.208 | Nicotine dependence, unspecified, with other nicotine-induced disorders |
| F17.209 | Nicotine dependence, unspecified, with unspecified nicotine-induced disorders |
| F17.21 | Nicotine dependence, cigarettes |
| F17.210 | Nicotine dependence, cigarettes, uncomplicated |
| F17.211 | Nicotine dependence, cigarettes, in remission |
| F17.213 | Nicotine dependence, cigarettes, with withdrawal |
| F17.218 | Nicotine dependence, cigarettes, with other nicotine-induced disorders |
| F17.219 | Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders |
| O99.33 | Tobacco use disorder complicating pregnancy, childbirth, and the puerperium |
| O99.330 | Smoking (tobacco) complicating pregnancy, unspecified trimester |
| O99.331 | Smoking (tobacco) complicating pregnancy, first trimester |
| O99.332 | Smoking (tobacco) complicating pregnancy, second trimester |
| O99.333 | Smoking (tobacco) complicating pregnancy, third trimester |
| O99.334 | Smoking (tobacco) complicating childbirth |
| O99.335 | Smoking (tobacco) complicating the puerperium |
| Z87.891 | Personal history of nicotine dependence |
| 0-9 | A-Z |
|---|---|
| F17 | Nicotine dependence |
| F17.2 | Nicotine dependence |
| F17.20 | Nicotine dependence, unspecified |
| F17.200 | Nicotine dependence, unspecified, uncomplicated |
| F17.201 | Nicotine dependence, unspecified, in remission |
| F17.203 | Nicotine dependence unspecified, with withdrawal |
| F17.208 | Nicotine dependence, unspecified, with other nicotine-induced disorders |
| F17.209 | Nicotine dependence, unspecified, with unspecified nicotine-induced disorders |
| F17.21 | Nicotine dependence, cigarettes |
| F17.210 | Nicotine dependence, cigarettes, uncomplicated |
| F17.211 | Nicotine dependence, cigarettes, in remission |
| F17.213 | Nicotine dependence, cigarettes, with withdrawal |
| F17.218 | Nicotine dependence, cigarettes, with other nicotine-induced disorders |
| F17.219 | Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders |
| O99.33 | Tobacco use disorder complicating pregnancy, childbirth, and the puerperium |
| O99.330 | Smoking (tobacco) complicating pregnancy, unspecified trimester |
| O99.331 | Smoking (tobacco) complicating pregnancy, first trimester |
| O99.332 | Smoking (tobacco) complicating pregnancy, second trimester |
| O99.333 | Smoking (tobacco) complicating pregnancy, third trimester |
| O99.334 | Smoking (tobacco) complicating childbirth |
| O99.335 | Smoking (tobacco) complicating the puerperium |
| Z87.891 | Personal history of nicotine dependence |
Formulary Reference Tool